CARsgen Therapeutics receives Orphan Medicinal Product designation from European Medicines Agency for CT041 CLDN18.2 CAR T Cells for treatment of gastric cancers

This targeted CAR-T product candidate for treatment of gastric cancer consists of patient's own T cells, genetically modified to express a humanized anti-CLDN18.2 chimeric antigen receptor (CAR) to treat patients with CLDN18.2-positive tumours. Three Phase 1b trials are underway.

Biospace Inc.